For the first target addressed in the partnership, the two companies reported the successful delivery of AI-designed, ...

AstraZeneca (LSE:AZN) recently announced that its investigational antibody, anselamimab, did not achieve statistical significance for its primary endpoint in AL amyloidosis, although it showed promise ...

USA-based Madrigal Pharmaceuticals today announced that it has entered into an exclusive global license agreement with CSPC ...

The idea is that SYH2086 can be paired with Rezdiffra, a selective thyroid hormone receptor agonist that became the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) ...

AI research is central to many of the deals. In April, French pharmaceutical giant Sanofi announced a $1.7 billion agreement ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

Out-licensing drugs to multinational corporations is a natural step for Chinese biotechs, but the recent rise in deals is ...

Madrigal Pharmaceuticals said on Wednesday it has entered into a licensing agreement worth up to $2 billion with China's CSPC Pharmaceutical Group to develop an oral GLP-1 drug for a serious form of ...

CSPC PHARMA (01093.HK) announced that it had entered into a strategic research collaboration agreement with AstraZeneca for the discovery and development of novel oral small molecu ...

AstraZeneca, Pfizer and other multinational drug companies have spent a record amount on medicines developed by Chinese biotechs this year, underscoring how Big Pharma is increasingly reliant on China ...

Further solidifying its research and development pipeline, AstraZeneca entered a strategic research collaboration in June with Shijiazhuang City-based CSPC Pharmaceuticals Group Limited.

China is being viewed by the biotech and life sciences industry as a threat to US innovation. One pharma CEO thinks it may not be the worst thing to happen to the industry.